Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2022-01-13 00:00:00 ET · period of report 2022-01-11 · accession 0001209191-22-003166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-01-13 | 2022-01-11 | FATE | Chu Yu-Waye | Senior VP Clinical Development | S - Sale | $48.51 | -3,965 | 121.8K | -3% | -$192.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-11 | S | D | 3,547 | $48.44 | 122,211 | D | — | — | (F2) Represents the weighted average sale price of the shares sold ranging from $47.68 to $48.67 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2 through 3. |
| 2 | Common | Common Stock | 2022-01-11 | S | D | 418 | $49.10 | 121,793 | D | — | — | (F3) Represents the weighted average sale price of the shares sold ranging from $48.71 to $49.25 per share. |